A group of scientists at VCU Massey Comprehensive Cancer Center has revealed a new genetic code that acts like a cancer ringleader, recruiting and deploying a gang of tumor cells to incite a biological turf war by invading healthy organs and overpowering the normal cells.

This discovery— published today, Dec. 9, in Nature Biotechnology —could unveil an entirely different understanding of the origins of cancer within the body, as well as offer insight into new treatment strategies that could target the growth of tumors in their earliest stages.

The study authors have also developed an intravenous therapy that empowers healthy cells to mount an immune response and build up a defensive resistance against these invading tumor cells. This treatment has already been proven effective in ovarian tumors, but the implications of this research could be universal to all cancer types.

In August, the Food and Drug Administration (FDA) granted accelerated approval of Tecelra (afamitresgene autoleucel)— the first T-cell receptor therapy for solid tumors—for people with inoperable or metastatic synovial sarcoma. Tecelra is a gene therapy created from a patient’s own T cells. A sample of cells is removed and genetically modified to express a natural T-cell receptor that targets MAGE-A4, an antigen expressed on cancer cells. In the Phase II SPEARHEAD-1 trial, the overall response rate was 43%, and 39% of responders were still doing well a year later.

Northwestern Medicine investigators have discovered new molecular mechanisms underlying DNA repair dysregulation in prostate cancer cells, findings that may inform the development of new targeted therapies for patients that have become resistant to standard treatments, according to a recent study published in Science Advances.

Qi Cao, Ph.D., the Anthony J. Schaeffer, MD, Professor of Urology, was senior author of the study.

DNA damage is a natural occurrence in cells caused by various intercellular and external stressors. However, if left unrepaired, this damage can lead to genetic mutations that can lead to the development of different diseases, including cancer.

Within a cell, DNA carries the genetic code for building proteins. To build proteins, the cell makes a copy of DNA, called mRNA. Then, another molecule called a ribosome reads the mRNA, translating it into protein. But this step has been a visual mystery; scientists previously did not know how the ribosome attaches to and reads mRNA.

Now, a team of international scientists, including University of Michigan researchers, has used advanced microscopy to image how ribosomes recruit to mRNA while it’s being transcribed by an enzyme called RNA polymerase (RNAP). Their results, which examine the process in bacteria, are published in the journal Science.

“Understanding how the ribosome captures or ‘recruits’ the mRNA is a prerequisite for everything that comes after, such as understanding how it can even begin to interpret the information encoded in the mRNA,” said Albert Weixlbaumer, a researcher from Institut de génétique et de biologie moléculaire et cellulaire in France who co-led the study.